Bill & Melinda Gates Foundation
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bill & Melinda Gates Foundation
Working for years to develop weekly or monthly oral drugs, Lyndra raises $101m and licenses commercial rights in six nations to Sun Pharma in a deal getting its lead product closer to the finish line.
Deal Snapshot: In Almirall’s first de novo artificial intelligence drug discovery and development collaboration, the company will pay up to $650m to work with Absci on two dermatology candidates.
Deal Snapshot: Previously partnered on CAR-T therapies for cancer and COVID-19 antivirals, AbbVie and Scripps’ discovery unit Calibr unveil a five-year extension, including new targets and preclinical candidates.
Private Company Edition: Venture capital mega-rounds of $100m or more held steady in April after a slow January and February then a surge in March, but VC fundraising is down overall this year. In recent raises, Enveda series B expanded to $119m, Vedanta brought in $106.5m and Convergent raised $90m.
- Academic and Research Institutions
- Other Names / Subsidiaries
- The Gates Foundation
- Gates MRI
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.